SlideShare une entreprise Scribd logo
1  sur  19
Télécharger pour lire hors ligne
Tenet’s Q4 2007 Earnings Call Prepared Remarks
                   February 26, 2008

Trevor Fetter, President and Chief Executive Officer

 Good morning everyone.


 This quarter we achieved a major milestone by generating positive growth in admissions. We
 also continued to demonstrate positive trends in several key areas and certain leading
 indicators have never looked stronger. I feel that the health and trajectory of this company is
 better than at any time in the recent past.


 This was the first time in nearly four years that we had positive admissions in a quarter.
 Because it was just slightly positive, I want to add some color to the statistic.


 First, we’ve had more consistent results among our regions than in past quarters, and we’ve
 continued to move more hospitals into positive admissions territory. Admissions in Florida
 stabilized significantly to just below breakeven, compared to the declines of more than 3
 percent that we had been reporting in recent quarters.


 More importantly, the improving trend has accelerated into the first quarter of 2008, with
 same-hospital admissions up 2.3 percent through January. Florida admissions growth was
 positive for the first time since Q104, with an increase of more than 2 percent for the month.
 This upward trend has continued into February in both Florida and across the company. Even
 the trend in outpatient visits has improved.


 Same-hospital commercial managed care revenues increased by almost 9 percent despite a
 nearly 2 percent decline in commercial admissions. This is the single largest quarterly
 revenue increase we’ve reported in five years. We are positioned for further pricing strength
 as a result of the numerous managed care contracts we announced recently. In fact, these
contracts, with United, Cigna and Blue Cross of California represent a third of our total
commercial managed care portfolio.


And once again we kept the growth in controllable expenses on a unit of service basis at or
below that reported by our peers.


The innovations we’ve made in the revenue cycle continue to produce tangible results, despite
the challenge represented by the continued double-digit increases in uninsured admissions.
Because of these efforts, we were able to increase our collection rates from both insured and
uninsured individuals.


We also improved sharply in the non-financial metrics which we believe are important to our
longer-term performance. These metrics are part of our Balanced Scorecard and incentive
plan, and we believe they are leading indicators of our continued progress. We break the
Balanced Scorecard into five areas, or pillars, which include quality, service, people, cost and
growth.


The first of our three non-financial metrics falls into our quality pillar. According to CMS’
most recently published Hospital Compare data, Tenet scores higher than any other investor-
owned hospital company in CMS’ core measures, and we have the third highest score among
the top 10 largest hospital systems in the country. We continue to hit all-time highs in our
quality statistics even as CMS adds challenging new metrics to the mix.


The next pillar is service. Our scores here improved as well, with physician satisfaction
increasing 2 ½ percent over the prior year and patient satisfaction increasing nearly 1 percent.


And in the people pillar, total employee turnover improved by more than 12 percent.
Employee satisfaction improved nearly 4 percent. And although it’s not a balanced scorecard
metric, I know you would find it interesting that our hospital CEO turnover in 2007 was just
under 4 percent. This compares to a 20 percent turnover among our hospital CEOs in 2006.




Q4 2007 Earnings Prepared Remarks                                                    Page 2 of 19
While we didn’t generate as much cash from working capital as we had planned, we did offset
   that at year-end with our other cash initiatives, which we expect will continue generating
   value going forward. Biggs will comment on those in a moment.


   Near the end of 2007, we engaged in a thorough business planning effort that resulted in the
   outlook we stated in this morning’s press release. This outlook envisions 2008 EBITDA in a
   range of $775 million to $850 million, and 2009 EBITDA of $1 billion or better.


   While I fully recognize the billion dollar objective represents a significant improvement from
   the EBITDA we generated in 2007, I believe we’ve set a clear path to achieving it. This will
   require strong and consistent performance on our part – capturing market share from
   competitors to meet our volume objectives, continuing to implement innovative techniques to
   offset the challenges on bad debt, and extending the progress that we’ve made in controlling
   costs and achieving enhanced pricing – but it is certainly within our reach.


   With that as an overview, let me turn the call over to our chief operating officer, Dr. Steve
   Newman, who will provide you with some commentary on what is driving our improvement
   in patient volumes. Steve…


Stephen Newman, M.D., Chief Operating Officer

SLIDE 6: Stephen L. Newman, M.D. – Chief Operating Officer
   Thanks, Trevor. And good morning, everyone. We made very gratifying progress in the
   fourth quarter that is continuing in the first quarter. In my opinion, our turnaround is
   accelerating and is increasingly evident in a number of areas.


SLIDE 7: Momentum Building in 3 Key Areas
   To show you why I believe this, I’ll give you a flavor for our momentum in three key areas:
   volumes, pricing and its relationship to our quality initiatives, and our progress in expanding
   our medical staffs. I’ll also touch on the improvements we’re driving in Florida and the
   successes we’ve achieved in our new managed care contracts.


   Q4 2007 Earnings Prepared Remarks                                                     Page 3 of 19
SLIDE 8: Volume Growth
  Let’s start with volumes. Fourth-quarter same-hospital aggregate admissions increased a
  tenth of a percentage point over Q406. That’s the first positive quarter for admissions growth
  in almost four years. January’s in-patient admission growth was 2.3 percent and February has
  continued that trend, so I think it’s clear that our volumes are on an upward trajectory. The
  progress in the fourth quarter and in January is especially gratifying when you remember that
  we had a mild flu season until four weeks ago.


  It’s not our normal practice to disaggregate volume results – and we make no promise to do
  this on a regular basis – but I think some drill down this time will help you understand the
  underlying trends we’re seeing. In our key Florida market, fourth-quarter in-patient
  admissions were down just three tenths of a point – our best performance there since Q404.
  In Palm Beach County fourth-quarter admissions actually increased 80 basis points. Four of
  our five Palm Beach hospitals had positive year-over-year admissions growth. Additional
  evidence of our Florida recovery is demonstrated by January admissions being up more than 2
  percent over January 2007.


  Our new Florida regional leader, Marsha Powers, has accelerated our physician recruitment,
  redirection and employment activities. We’re confident we’re finally on the road to
  sustainable growth in that important market.


  Now I can’t resist saying a few words about the remarkable and continuing progress of our
  Philadelphia market. Both Hahnemann University Hospital and St. Christopher’s Hospital for
  Children generated strong volume gains in the fourth quarter. As you know, we expected to
  gain volume at St. Chris because of the closure of Temple University Hospital for Children.
  But the gains at St. Chris have far exceeded what can be attributed just to that new affiliation.
  For the quarter, admissions at St. Chris were up 20 percent, which translates to an additional
  498 admissions compared with the same quarter the year before. Also contributing to that
  success at St. Chris are our aggressive outreach activities beyond the five-county metro
  Philadelphia area as well as the addition of new high-end services like bone marrow
  transplantation.


  Q4 2007 Earnings Prepared Remarks                                                     Page 4 of 19
Meantime, Hahnemann’s admissions were up nearly one percent. We are continuing to work
   with Drexel University’s School of Medicine to grow our faculty practices at Hahnemann and
   St. Chris to benefit the educational, research and patient care missions of both organizations.


   We’re in the process of expanding our facilities in Philadelphia in anticipation of future
   growth, but we have sufficient capacity there today to handle the projected increases in
   volume over the near term.


   California was another bright spot in the quarter. Our California hospitals had an aggregate
   increase in admissions of 3.2 percent over the fourth quarter of 2006. We knew we’d see an
   improvement in the quarter because of our acquisition of the Stanislaus Behavioral Health
   Center in Modesto, but we also had noticeable increases in two of our other key California
   markets – the Palm Springs area and Orange County. For example, Fountain Valley was up
   3.8 percent and Desert Regional increased admissions by 9 percent for the quarter. The
   Stanislaus facility added 263 admissions to the California aggregate total. But, even without
   that added volume, California admissions were up a solid 2.4 percent.


   We encountered some volume weakness in our Texas and Southern States markets, but we
   believe that softening will be temporary. One weak spot in the quarter was El Paso, but we
   have already seen improved admission volumes in early 2008. A major refurbishing project
   at another one of our Texas hospitals temporarily closed a number of our medical-surgical
   units there. In our Houston market, we’re about to pass the first anniversary of an aggressive
   new physician-owned competitor that hurt another of our hospitals. We expect that situation
   to normalize in the near future.


   The challenges in our Southern States region were very local in the fourth quarter. These
   resulted from slightly higher than expected physician attrition. We have taken swift action to
   accelerate our volume-building activities in both the Southern States and Texas markets.


SLIDE 9: Volume Growth (Cont.)



   Q4 2007 Earnings Prepared Remarks                                                    Page 5 of 19
I’ll wrap up this discussion of volumes with brief comments on surgery volumes and
   commercial managed care admissions.


   Our total surgeries rose three-tenths of a point compared to Q406. Out-patient surgeries were
   up eight-tenths of a point while in-patient surgeries were down four-tenths of a point. This
   represents a dramatic improvement over the losses we had absorbed in total surgeries during
   prior quarters. As recently as the first half of 2007, quarterly declines in surgeries were 5
   percent or more.


   Same-hospital commercial managed care admissions were down 1.8 percent in the fourth
   quarter. Our commercial managed care volume weakness was concentrated in Texas and the
   Southern States. Specifically, three hospitals located within our Texas market and Southern
   States region were responsible for 96 percent of this decrease company wide. As I just
   described a few moments ago, we expect that situation to stabilize in the near future.


   We continued to generate growth in many of the TGI service lines I highlighted in the third
   quarter. Commercial urologic surgery admissions were up 8.2 percent, ENT surgery was up
   19 percent, orthopedic surgery was up 0.3 percent, neurosurgery was up 3.7 percent, and
   vascular surgery was up 16 percent for the fourth quarter. Meantime, obstetrics was down 2.7
   percent, and open heart surgery was down nearly 14 percent or 68 procedures.


   Overall, I’d say the key takeaway about our latest admissions performance is that we are
   continuing to drive growth in the service lines we targeted as part of our Targeted Growth
   Initiative (TGI). As you recall, over the past three years through TGI we painstakingly
   identified the service lines with the best growth and profit potential at each of our hospitals.


SLIDE 10: Pricing Gains . . . achieving our objectives
   Now let’s talk about pricing. We successfully renegotiated several of our major managed care
   contracts in the fourth quarter and the first six weeks of 2008. With the completion of new,
   multi-year contracts with United, Aetna, CIGNA and Blue Cross of California, we now have
   secured full network participation with every one of our major commercial payers for all of
   our hospitals, freestanding ambulatory surgery centers, diagnostic imaging centers and


   Q4 2007 Earnings Prepared Remarks                                                      Page 6 of 19
physician practices. These new contracts will also automatically add any new facilities or
   practices we might acquire during the term of the agreements. As you know, making sure that
   all our facilities are network providers has been a top priority of our managed care strategy,
   and I am pleased to tell you that we have now achieved that goal with our recently completed
   contracts.


   Our managed care pricing – including managed government programs – was up sharply with
   net inpatient revenue per admission increasing 9.4 percent and net outpatient revenue per visit
   up 9.0 percent in the fourth quarter. I believe that is a reflection of a number of focused
   efforts to align our Targeted Growth Initiative with our managed care strategy.


   Another of our managed care goals has been to qualify for as many managed care Centers of
   Excellence programs as possible. Additionally, in the last four months we have executed two
   contracts that actually provide potential incremental reimbursement to our hospitals for
   meeting mutually agreed upon clinical quality goals.


SLIDE 11: Physician Relationships: Recruiting More Doctors
   Before I conclude, I want to share with you the latest results of our efforts to expand medical
   staffs at all our hospitals. In the fourth quarter, net of normal attrition, we added 241 new
   active staff physicians to our hospitals. For all of 2007, we added a net total of 1,086
   physicians. As you know, this has been a critical priority for us. The success of our efforts in
   this area is especially gratifying for me, and it bodes well for the future growth of our
   hospitals.


   I truly believe that this progress in physician recruitment is a key indicator of our future
   volume growth. In the last year, we have increased the number of physicians with privileges
   to admit patients to our hospitals by almost 9 percent. It will take time for these new
   relationships to fully mature, but this growth represents a dramatic reversal of the erosion in
   our affiliated physician base that we experienced over the past several years. If I had to point
   to the one item that gives me the most optimism about our future at Tenet, this would be it.




   Q4 2007 Earnings Prepared Remarks                                                      Page 7 of 19
Through our Physician Relationship Program, we visited 4,720 physicians during the fourth
   quarter. Of those we visited, we saw an increase in admissions of 2.5 percent from physicians
   who already had staff privileges at our hospitals. We also visited 437 physicians who did not
   have privileges at our hospitals, and we expect many of them to apply for privileges as a
   result of our visits. This is an integral part of our strategy to gain market share in many of our
   fiercely competitive markets.


   To assist in these and all our volume-building efforts, during the fourth quarter we hired
   Lloyd Mencinger to lead our business development, marketing, advertising, physician
   recruitment and the Physicians Relationship program. Lloyd has years of experience in
   business development, working at both Baxter and Boston Scientific.


SLIDE 12: Summary - Operations
   So, to conclude, the bottom line from my perspective is this: In the fourth quarter, we made
   progress in all the major drivers of performance in our business. We grew in-patient volumes
   for the first time in almost four years. We’ve continued to do that in 2008. From a pricing,
   quality and physician recruitment perspective, we continue to grow our channels for new
   business. Overall, I am very pleased by the trends I am seeing, and I am confident that we
   will continue to see improvements in 2008.


   With that, I will turn things over to Biggs Porter, our chief financial officer. Biggs?



Biggs Porter, Chief Financial Officer

   Thank you, Steve, and good morning everyone.


   In the interest of time, I’m not going to repeat a lot of the numbers in our earnings release or
   10-K. I’ll limit my comments to providing a relevant context for our disclosures.




   Q4 2007 Earnings Prepared Remarks                                                         Page 8 of 19
In the fourth quarter, we benefited from pricing, cost control, bad debt mitigation and
stabilized volume. We finished the year with adjusted EBITDA in the middle of our last
outlook and just within the outlook range we started out with last March.


There were two unusual items in the quarter which largely offset each other.


The first was a net charge of $12 million related to year-end accruals for compensation and
benefits. This included adjustments to a predecessor company’s pension plan, union
settlement costs in Florida, workers compensation adjustments and year-end incentive plan
accruals.


The other item is a favorable adjustment to our bad debt reserve of $19 million. This reserve
is set through the use of an 18-month “look-back” on our collection history. As you know,
our collection rates continue to show modest improvement across most customer segments.


In recent quarters our results have often included cost report settlements, generally with
favorable impact. The impact this quarter was effectively a net zero.


With that brief analysis in mind, let me offer a few thoughts on the drivers that got us to those
results.


Steve has already covered volumes, so without detail, I will just reiterate how pleased we are
to see aggregate positive growth, particularly considering the well advertised strong
headwinds in the industry. I also want to note that our uninsured and charity volumes actually
declined in January – so the positive 2.3 percent in admission growth Trevor referred to
earlier will contribute to our bottom line.


Now on to revenues,


Fourth quarter same hospital revenues rose to $2.2 billion, an increase of 6 percent. Because
of the essentially breakeven volume growth, this 6 percent revenue increase was principally
due to pricing.


Q4 2007 Earnings Prepared Remarks                                                     Page 9 of 19
Slide 18 on the web shows that we experienced solid progress in all our key pricing metrics.
As a summary metric, normalized for cost report adjustments in 2006, net patient revenues
per adjusted admission were up 4.9 percent.


As a number of important contracts including Blue Cross of California and CIGNA were not
effective until the first quarter of 2008, we anticipate additional pricing increases to contribute
to our 2008 earnings. Substantially all of our existing contracts, including those negotiated in
2007, also have 2008 and 2009 escalators built in.


We have good visibility into our managed care pricing for the next two years, because
approximately 80 percent of our commercial rates for 2008 and over 60 percent for 2009 are
already covered in signed contracts.


Turning to costs,


Same hospital controllable operating expense per adjusted patient day increased by 5.1
percent. As I mentioned a moment ago, this included a $12 million expense accrual for
compensation and benefits expense. If we normalize for that accrual and the higher supplies
expense on greater implant utilization, our expenses would have been in line with the
expectations we had going into the quarter, with a number of lesser puts and takes among the
other elements of our controllable costs.


It is also important to note that we had a $13 million reduction in malpractice expense in the
quarter. Based on the investment we have made in clinical quality, we are pleased to see this
reduction. Unfortunately, we also had some poorer than expected cost performance in a few
of our hospitals that lost volume in the quarter. We believe, as Steve mentioned, that both the
volume and cost effects of that will reverse themselves.


On Bad Debt,




Q4 2007 Earnings Prepared Remarks                                                     Page 10 of 19
Same hospital uninsured admissions rose by 10 percent in the fourth quarter and revenues
from the uninsured rose by 17.5 percent. Let me remind you, that this increase in uninsured
revenue has been influenced by our recent efforts to improve the accuracy of acuity capture in
our emergency departments.


Any change in uninsured billings creates a parallel effect on bad debt expense. We estimate
that $19 million of the $24 million in the uninsured revenue increase year over year is
attributable to our efforts to improve the accuracy of acuity capture in our emergency
departments and, to a much lesser degree, charge master increases. The corresponding $17
million bad debt increase has no effect on the bottom line since it is offset by revenue
increases. Also, since we modified our ED charge capture process in the second quarter of
2007, we do not expect similar year-over-year increases in bad debt from ED charge capture
in 2008.


Growth in bad debt expense from higher uninsured admissions was approximately $5 million.
Accordingly, the combined effect on bad debt of uninsured admission growth and pricing
compared to last year is approximately $22 million dollars.


Offsetting the adverse impact on bad debt expense from the growth in the uninsured has been
continued progress on improving collections. Through focused effort, we have been
successful in raising self-pay collection rates to 36 percent in the fourth quarter from 32
percent a year ago.


Managed care collection rates also moved up to 98 percent in the fourth quarter, from 97
percent a year ago due to lower denials attributable to our previously discussed efforts to
improve this area. These include greater Interqual screening, clearer contracting
arrangements and better front-end processes.


This improvement in collection experience led to the recording of the $19 million favorable
adjustment to our bad debt reserves I mentioned at the beginning of my remarks. This
compared to an $8 million favorable adjustment last year.



Q4 2007 Earnings Prepared Remarks                                                    Page 11 of 19
In addition to the overall collection performance improvements, we also resolved older
managed care accounts which had been heavily reserved. The favorable effect of this on bad
debt expense was offset by what we see primarily as the seasonal aging of self-pay accounts.
Like others in the industry, we typically experience a slowing of payments in the fourth
quarter as our patients deal with year-end and holiday pressures on their household budgets.
This is typically reversed by the end of the first quarter.


So to summarize, same hospital bad debt expense grew over the prior year fourth quarter by
$15 million. Uninsured volumes contributed $5 million to this increase, pricing contributed
$17 million, and the net year-over-year reserve adjustment due to improved collections
experience was a favorable offset of $10 million. Other variances, including the effects of the
settlement of managed care disputes, netted to $3 million.


While same hospital uninsured admissions and revenues were up over prior year fourth
quarter, charity was down, making this another quarter in which there are opposing trends.
Although not easily traced, we are optimistic that our strategies to emphasize favorable
product lines and manage elective admissions and visits by uninsured are mitigations to what
is a key risk in the industry. I emphasize the word “elective” in this regard. We also continue
to drive on best practices in our billing and collection activities.


I just did a fourth quarter year-over-year comparison on bad debts, but if you compare
sequentially, it is important to note that uninsured revenues were actually down from the third
quarter of this year.


Turning to cash flow and capital expenditures,


We ended the year with our cash balance within our expected range. In accomplishing that
we didn’t do as well on cash from operations as we expected and spent slightly more capital,
which should just be a matter of timing, but we continued to find other positive sources of
cash on our balance sheet, which are more permanent in nature. As I will discuss in a
moment, the variances to our expectations in the fourth quarter will turn to expectations of
improved free cash flow and cash generated from operations in 2008.


Q4 2007 Earnings Prepared Remarks                                                  Page 12 of 19
Cash from operations and free cash flow become sequentially more important metrics as we
proceed through the next few years and approach the refinancing of our debt. In this respect
you should consider 2007 as the year of heaviest investment for the company, with volumes
starting to show the benefits, and with us well positioned to show improved earnings, cash
flow and return on investment going forward.


Capital expenditures in continuing operations were $300 million in the quarter. This figure
was slightly above the higher end of our range we shared with you in our third quarter call
and is roughly equivalent to the amount we spent last year. One of the influences on the
higher spending in this year’s fourth quarter was that we wanted to make sure 2007 was our
“catch up” year as we have previously projected. This leaves us with a manageable amount of
carryover projects.


On the Web we have included on Slide 23 a listing of the major capital projects of 2007. At
this point I expect capital spending in 2008 to be little more front end loaded into the first and
second quarters


Also contributing to the higher level of capex in the fourth quarter, favorable weather has
allowed us to accelerate the construction of our Sierra Providence East Medical Center in El
Paso, which will now open a month earlier than we had expected. This generated $22 million
in capex in the fourth quarter. We have also started the construction of a replacement hospital
for our East Cooper facility outside of Charleston, South Carolina on which we spent $2
million in the fourth quarter.


With respect to cash flow,


Adjusted cash flow provided from continuing operations came in at $127 million for the
fourth quarter and was lower than anticipated. The primary deviation was in working capital.
We typically expect to see a more significant build-up in accounts payable and accrued
liabilities at year-end than we saw this year. On the pure accounts payable side, we saw the
increase we anticipated in the payment terms set up in the system. However, there was a $63


Q4 2007 Earnings Prepared Remarks                                                    Page 13 of 19
million decline in book overdrafts at December 2007 compared to 2006 which occurred due
to the timing of our year-end check processing. This book overdraft should return to more
normal levels in 2008, thus creating a source of cash flow in 2008.


We also experienced a $31 million build up in Accounts Receivable. This is attributable to
the effects of higher revenues and lower reserving for bad debts. This therefore doesn’t
reflect bad performance. It in fact reflects improved collectability. However, we did not
generate the net improvement we targeted in accounts receivable. In the fourth quarter of this
year we did resolve a number of our older managed care receivables, but this was offset by
the seasonal aging of self-pay accounts I referred to earlier. Other than that, we were overly
optimistic in our ability to reduce accounts receivable over the course of one quarter. We
believe it is going to take a few more quarters into 2008 to accomplish this reduction.


Just to summarize the influences on 2007 in total, we had a net reduction in our book
overdraft of $63 million, a reduction in accounts receivable credit balances of $54 million,
and non-cash income related to prior year cost report adjustments of approximately $35
million. Not all of these affect cash from continuing operations dollar for dollar, but they did
have a significant impact. We do not expect similar aggregate impact from these items in
2008.


Accordingly, in 2008, as we indicated in the release, we anticipate having adjusted cash
provided from operating activities of $400 to $500 million. This compares to $209 million in
2007 for an improvement in the range of $190 million to $290 million. Higher EBITDA is
expected to contribute $75 to $150 million of this improvement. The remainder of the
improvement includes a restoration of a more normal book overdraft position at year-end
2008, the two day reduction in accounts receivable we previously stated as an objective for
the fourth quarter of 2007, and a reduction in the rate of pay down of credit balances.


As I have said previously, we have engaged in a review to increase the efficiency of our
balance sheet and correspondingly free up cash and increase return on invested capital. Let
me now turn to the progress we achieved towards this end in the fourth quarter. We added
$129 million in cash from these initiatives in 2007, of which $97 million was in the fourth


Q4 2007 Earnings Prepared Remarks                                                   Page 14 of 19
quarter. At the corporate level, we monetized certain investments previously residing in our
insurance subsidiaries and liquidated the cash surrender value of life insurance policies. We
anticipate that continuing efforts to execute on this initiative can generate incremental cash
ranging from $400 million to $600 million over the next 24 months. These include the sale of
our medical office buildings, the recapitalization of Broadlane, in which we hold a 48%
interest, and the sale or monetization of other excess land, buildings and other underutilized
and inefficient assets. Since some of these items require marketing and price negotiation, I
am not going to break them down into separate component values. Because the timing and
value is within a broad range, at this time this additional cash is not in our 2008 year-end
outlook.


Before I turn to the outlook for 2008, I want to comment on the impairments we recorded in
the quarter. They were much reduced over the prior year and included no impairments of
goodwill. This is a sign that our turnaround is progressing and that our forecasts at the
hospital level are for a broad based recovery. The single biggest reason for the impairments
we recorded was the prospective reduction of Medicaid funding in Georgia and not
attributable to our execution of our turn around strategies


With respect to capital spending,


For 2008 we expect Capital expenditures to be in the range of $600 to $650 million. This
includes $82 million for new hospital construction, $32 million for seismic and American
Disabilities Act requirements, and $25 million for Outpatient growth.


Investors have often asked us to identify the portion of our capital expenditures which can be
thought of as “maintenance” capex. Because of the many judgment calls necessary to
distinguish maintenance capex from capital expenditures intended to grow the business, we
have been reluctant to specify a number. By example, if we replace an old 4-slice CT scanner
with a 64-slice scanner is that replacement or expansion? Intuitively, I would call that
maintenance capital, although it may expand our capabilities. Our answer to date to the
question of maintenance capital has been to point investors to the sum of depreciation,
amortization and lease expense, net of implicit interest, which was approximately $500


Q4 2007 Earnings Prepared Remarks                                                    Page 15 of 19
million in 2007. Another way to look at this might be how much did we spend on our current
core hospitals over the period 2003 to 2005 excluding physical expansion and new hospital
construction. This was approximately $400 million per year over that period. If you look at
the same statistic for the last five years, it was approximately $450 million. If you put all this
together, then it would suggest an estimate of “maintenance capital” at approximately $400 to
$500 million.


Having said that, the lower end of the range, or $400 million, would likely not sustain our
competitive position over a long term. Also, this excludes seismic and American Disability
Act requirements as well as capital for expansion of the enterprise or in certain cases the
construction or technology spending necessary to protect market share based on the action of
our competitors. If you include those, it takes us up to the $600 to $650 million level we have
spoken to as a reasonable level of average annual spend to meet regulatory requirements, and
sustain and grow the enterprise.


Moving to the Outlook,


We have provided extensive detail with regard to our 2008 Outlook in this morning’s press
release, so I won’t repeat all the line item detail here.


The 2008 Outlook includes an expectation of adjusted EBITDA in the range of $775 to $850
million – or growth of 10 to 20 percent over the $701 million of adjusted EBITDA for 2007.
Much of the “heavy lifting” necessary to achieve performance at this level has already been
accomplished. I’m referring here to the contracts we recently signed with our major managed
care payers, and the other pricing initiatives and cost efficiencies we implemented last year
that will achieve full run rate in 2008. Having said that, there clearly also were some set
backs, most notably the $60 million revenue loss from the Medicaid reductions in Georgia
and Florida.


We haven’t given a 2008 outlook previously, and over the course of last year, we maintained
a 2009 outlook which, while having a lot of subjectivity, was between $1 and $1.1 billion of
adjusted EBITDA. In the fourth quarter we updated the analysis indicating that of the $100


Q4 2007 Earnings Prepared Remarks                                                     Page 16 of 19
million of risk inherent in that range, $60 million had now been consumed by the Medicaid
reductions I just referred to in Georgia and Florida. This still left us with a 2009 outlook of
$1 billion or higher going into the detailed 2008 planning process. We have completed that
process and continue to believe that the $1 billion or more of EBITDA in 2009 is achievable,
although projecting two years out is by its nature very subjective.


As I said, we have given a range of $775 to $850 million for EBITDA in 2008. Clearly, if we
do not perform in the upper half of that range in 2008, reaching $1 billion or more in 2009
becomes a very significant challenge. As I said though, we continue to believe the objective
is achievable, based on our progress in pricing, cost control and positive progress toward our
volume objectives.


If you ask me where the greatest areas of risk are that lead to the 2008 range or would cause
us not to make the 2009 target, I would say the following two things stand out:
   •   First: Although it seems we are turning the corner on volumes, this is, of course, a
       very subjective estimate. Equally important, mix between patients and payer
       categories can have a significant influence. To obtain $850 million in 2008 or $1
       billion in 2009, we either need to have relatively stable mix overall and a limited
       increase in the percentage of uninsured and charity volumes combined, or we need to
       get offsetting yield from our bad debt initiatives.
   •   Second: We need to have broad-based volume growth. If we achieve our aggregate
       volume objectives, but volumes remain volatile at the hospital level, it will remain
       difficult to capture the operating leverage of fixed cost absorption. Although we have
       seen a reduction in the variability of performance at the hospital level overall, if we
       have a significant number of hospitals that suffer volume decline in 2008, that will
       make the achievement of an aggregate 40 percent yield on volume growth more
       challenging.


In slide 26 on the web, we have included a sample walk forward from 2007 actual results to
2008 at $850 million and 2009 at $1 billion of EBITDA. This is a sample walk forward,
illustrating one path to our objective of $1 billion, or more, of adjusted EBITDA in 2009. It is
not intended to give a series of spot estimates or line item guidance. There are certainly other

Q4 2007 Earnings Prepared Remarks                                                    Page 17 of 19
combinations of line item performance which would produce the same, or higher or lower
results. Having said that, this walk forward shows how the cost and price actions drive value
relative to the more subjective estimates of volume and mix. In a nut shell, volumes drive
approximately 33 percent of the necessary improvement in the walk forward from an adjusted
2007 starting point, with our cost and price actions providing the rest. You may recall that
initiatives in place by the end of 2007 were estimated to achieve $118 million of improvement
in 2008 and 2009 compared to that achieved in 2007. In the walk forward, the combined
EBITDA effect of the initiatives now amount to $162 million, with $33 million related to
revenue and $129 million related to cost. We have not assigned any value into the walk
forward for our bad debt initiatives. We have thus implicitly assumed that the financial
contribution of our bad debt initiatives will act to mitigate any potential increase in the
uninsured or under-insured.


The walk forward shows the effect of our cost and price actions and their effect on 2008
relative to 2007 in order to bridge to our prior disclosures of these initiatives. Since these are
now imbedded in our recent actual results and in our budgets, subject primarily to just full run
rate benefits, I will probably not keep isolating them going forward as they have become
integral to our operations and are no longer discrete. This does not mean that we are not
tracking execution of those plans and budgets. We are.


In terms of the incremental lift from rate parity adjustments in managed care pricing we
reflected in the walk forward, I can report that we are now negotiated on 100 percent of this in
2008 and 80 percent in 2009. There is still some potential additional pricing upside beyond
those numbers. So, as I said before, we feel very confident about our pricing estimates,
subject to any unforeseen regulatory change or mix changes.


You will note that the walk forward starts by backing two amounts out from the $701 million
2007 adjusted EBITDA starting point:
   1) the effect of the 2008 Georgia and Florida Medicaid reductions, and, conservatively,
   2) $40 million of the 2007 prior year cost report income




Q4 2007 Earnings Prepared Remarks                                                     Page 18 of 19
We may, in fact, have some effect of cost report adjustments in 2008 or 2009, but for now, we
have taken $40 million of cost report adjustments out of the walk forward. By eliminating
these two items at the start, our 2007 starting point for the walk-forward is a conservative
$601 million.


This conservative starting point of $601 million does make us more reliant upon volumes than
in our prior walk forward. It now takes growth in volume-related revenues over the two year
period in this sample walk forward, of approximately 2.2 percent in 2008 and 1.7 percent in
2009. Please remember that approximately 1 percent of this volume growth in 2008 is
expected from the recent additions of Stanislaus and the closing of Temple Children’s
hospital.


Last year after we gave our 2006 results and 2007 outlook, some analysts tried to annualize
our fourth quarter as a means of estimating what the next year should look like. I caution
against this as it does not consider the effect of projected volume growth and the full run rate
benefit of our 2007 initiatives. It also would not reflect that we have negotiated price
increases on contracts beginning as early as January 1 of this year and that our annual wage
increases are phased in later and are primarily in October, creating timing advantage between
price and cost escalation.


I know that was a lot to digest, so before we go to Q&A, I’d like to summarize briefly,
   •   we showed real progress on volumes and pricing and took significant cost actions in
       the quarter,
   •   we believe this progress is sustainable and that we can continue to leverage those
       actions to produce much improved results in 2008 and 2009,
   •   and, we are driving on cash and return on invested capital as a key indicator of
       shareholder value growth.


Let me now ask our operator to assemble the queue for questions.




Q4 2007 Earnings Prepared Remarks                                                   Page 19 of 19

Contenu connexe

En vedette

tenet healthcare _Rel_2008_Q4_FINAL_
tenet healthcare _Rel_2008_Q4_FINAL_tenet healthcare _Rel_2008_Q4_FINAL_
tenet healthcare _Rel_2008_Q4_FINAL_finance42
 
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentat
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentatSlides_2009_03_FINAL_PRINTVERSIONBarclaysPresentat
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentatfinance42
 
tenet healthcare CY08Sept10QDraftFINAL
tenet healthcare CY08Sept10QDraftFINALtenet healthcare CY08Sept10QDraftFINAL
tenet healthcare CY08Sept10QDraftFINALfinance42
 
TenetQ206PreparedRemarks
TenetQ206PreparedRemarksTenetQ206PreparedRemarks
TenetQ206PreparedRemarksfinance42
 
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102finance42
 
TenetQ207PreparedRemarks
TenetQ207PreparedRemarksTenetQ207PreparedRemarks
TenetQ207PreparedRemarksfinance42
 

En vedette (6)

tenet healthcare _Rel_2008_Q4_FINAL_
tenet healthcare _Rel_2008_Q4_FINAL_tenet healthcare _Rel_2008_Q4_FINAL_
tenet healthcare _Rel_2008_Q4_FINAL_
 
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentat
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentatSlides_2009_03_FINAL_PRINTVERSIONBarclaysPresentat
Slides_2009_03_FINAL_PRINTVERSIONBarclaysPresentat
 
tenet healthcare CY08Sept10QDraftFINAL
tenet healthcare CY08Sept10QDraftFINALtenet healthcare CY08Sept10QDraftFINAL
tenet healthcare CY08Sept10QDraftFINAL
 
TenetQ206PreparedRemarks
TenetQ206PreparedRemarksTenetQ206PreparedRemarks
TenetQ206PreparedRemarks
 
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102
tenet healthcare 1stQuarterCalendarFiscalYr03_10K123102
 
TenetQ207PreparedRemarks
TenetQ207PreparedRemarksTenetQ207PreparedRemarks
TenetQ207PreparedRemarks
 

Similaire à tenet healthcare EarningsPreparedRemarks

TenetQ107PreparedRemarks
TenetQ107PreparedRemarksTenetQ107PreparedRemarks
TenetQ107PreparedRemarksfinance42
 
tenet healthcare Q308EarningsRemarks
tenet healthcare Q308EarningsRemarkstenet healthcare Q308EarningsRemarks
tenet healthcare Q308EarningsRemarksfinance42
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarksfinance42
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarksfinance42
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarksfinance42
 
TenetQ106PreparedRemarks
TenetQ106PreparedRemarksTenetQ106PreparedRemarks
TenetQ106PreparedRemarksfinance42
 
TenetQ406PreparedRemarks
TenetQ406PreparedRemarksTenetQ406PreparedRemarks
TenetQ406PreparedRemarksfinance42
 
tenet healthcare Q208Scripts_Combined
tenet healthcare Q208Scripts_Combinedtenet healthcare Q208Scripts_Combined
tenet healthcare Q208Scripts_Combinedfinance42
 
quest diagnostics 7_24_07DGXQ22007CallTranscriptforweb
quest diagnostics 7_24_07DGXQ22007CallTranscriptforwebquest diagnostics 7_24_07DGXQ22007CallTranscriptforweb
quest diagnostics 7_24_07DGXQ22007CallTranscriptforwebfinance34
 
quest diagnostics q1 2005
quest diagnostics q1 2005quest diagnostics q1 2005
quest diagnostics q1 2005finance34
 
TenetQ306PreparedRemarks1
TenetQ306PreparedRemarks1TenetQ306PreparedRemarks1
TenetQ306PreparedRemarks1finance42
 
quest diagnostics 10_19transcriptforweb
quest diagnostics 10_19transcriptforwebquest diagnostics 10_19transcriptforweb
quest diagnostics 10_19transcriptforwebfinance34
 
InvestorDay2008Transcript_FINAL1
InvestorDay2008Transcript_FINAL1InvestorDay2008Transcript_FINAL1
InvestorDay2008Transcript_FINAL1finance42
 
Medical Facilities Corporation - 2019 Annual Report
Medical Facilities Corporation - 2019 Annual ReportMedical Facilities Corporation - 2019 Annual Report
Medical Facilities Corporation - 2019 Annual ReportSharePitch
 
Tenet2006NPS
Tenet2006NPSTenet2006NPS
Tenet2006NPSfinance42
 
mckesson Letter to Stockholders 2005
mckesson Letter to Stockholders 2005mckesson Letter to Stockholders 2005
mckesson Letter to Stockholders 2005finance2
 
Fiscal 2005 Letter to Stockholders
Fiscal 2005 Letter to Stockholders Fiscal 2005 Letter to Stockholders
Fiscal 2005 Letter to Stockholders finance2
 
Blog 13 ED Address to AGM 2016
Blog 13 ED Address to AGM 2016Blog 13 ED Address to AGM 2016
Blog 13 ED Address to AGM 2016George Kurzawa
 
cardinal health 2008 Annual Report
cardinal health 2008 Annual Reportcardinal health 2008 Annual Report
cardinal health 2008 Annual Reportfinance2
 
quest diagnostics Q308_Transcript
quest diagnostics Q308_Transcriptquest diagnostics Q308_Transcript
quest diagnostics Q308_Transcriptfinance34
 

Similaire à tenet healthcare EarningsPreparedRemarks (20)

TenetQ107PreparedRemarks
TenetQ107PreparedRemarksTenetQ107PreparedRemarks
TenetQ107PreparedRemarks
 
tenet healthcare Q308EarningsRemarks
tenet healthcare Q308EarningsRemarkstenet healthcare Q308EarningsRemarks
tenet healthcare Q308EarningsRemarks
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarks
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarks
 
tenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarkstenet healthcare QuarterEndedDecember312008PreparedRemarks
tenet healthcare QuarterEndedDecember312008PreparedRemarks
 
TenetQ106PreparedRemarks
TenetQ106PreparedRemarksTenetQ106PreparedRemarks
TenetQ106PreparedRemarks
 
TenetQ406PreparedRemarks
TenetQ406PreparedRemarksTenetQ406PreparedRemarks
TenetQ406PreparedRemarks
 
tenet healthcare Q208Scripts_Combined
tenet healthcare Q208Scripts_Combinedtenet healthcare Q208Scripts_Combined
tenet healthcare Q208Scripts_Combined
 
quest diagnostics 7_24_07DGXQ22007CallTranscriptforweb
quest diagnostics 7_24_07DGXQ22007CallTranscriptforwebquest diagnostics 7_24_07DGXQ22007CallTranscriptforweb
quest diagnostics 7_24_07DGXQ22007CallTranscriptforweb
 
quest diagnostics q1 2005
quest diagnostics q1 2005quest diagnostics q1 2005
quest diagnostics q1 2005
 
TenetQ306PreparedRemarks1
TenetQ306PreparedRemarks1TenetQ306PreparedRemarks1
TenetQ306PreparedRemarks1
 
quest diagnostics 10_19transcriptforweb
quest diagnostics 10_19transcriptforwebquest diagnostics 10_19transcriptforweb
quest diagnostics 10_19transcriptforweb
 
InvestorDay2008Transcript_FINAL1
InvestorDay2008Transcript_FINAL1InvestorDay2008Transcript_FINAL1
InvestorDay2008Transcript_FINAL1
 
Medical Facilities Corporation - 2019 Annual Report
Medical Facilities Corporation - 2019 Annual ReportMedical Facilities Corporation - 2019 Annual Report
Medical Facilities Corporation - 2019 Annual Report
 
Tenet2006NPS
Tenet2006NPSTenet2006NPS
Tenet2006NPS
 
mckesson Letter to Stockholders 2005
mckesson Letter to Stockholders 2005mckesson Letter to Stockholders 2005
mckesson Letter to Stockholders 2005
 
Fiscal 2005 Letter to Stockholders
Fiscal 2005 Letter to Stockholders Fiscal 2005 Letter to Stockholders
Fiscal 2005 Letter to Stockholders
 
Blog 13 ED Address to AGM 2016
Blog 13 ED Address to AGM 2016Blog 13 ED Address to AGM 2016
Blog 13 ED Address to AGM 2016
 
cardinal health 2008 Annual Report
cardinal health 2008 Annual Reportcardinal health 2008 Annual Report
cardinal health 2008 Annual Report
 
quest diagnostics Q308_Transcript
quest diagnostics Q308_Transcriptquest diagnostics Q308_Transcript
quest diagnostics Q308_Transcript
 

Plus de finance42

saic annual reports 2003
saic annual reports 2003saic annual reports 2003
saic annual reports 2003finance42
 
saic annual reports 2004
saic annual reports 2004saic annual reports 2004
saic annual reports 2004finance42
 
saic annual reports 2005
saic annual reports 2005saic annual reports 2005
saic annual reports 2005finance42
 
saic annual reports 2006
saic annual reports 2006saic annual reports 2006
saic annual reports 2006finance42
 
saic annual reports 2007
saic annual reports 2007saic annual reports 2007
saic annual reports 2007finance42
 
saic annual reports 2008
saic annual reports 2008saic annual reports 2008
saic annual reports 2008finance42
 
terex Merrill050808
terex Merrill050808terex Merrill050808
terex Merrill050808finance42
 
terex BofA050808
terex BofA050808terex BofA050808
terex BofA050808finance42
 
terex Merrill050808
terex Merrill050808terex Merrill050808
terex Merrill050808finance42
 
terex BofA050808
terex BofA050808terex BofA050808
terex BofA050808finance42
 
terex Sanford053008
terex Sanford053008terex Sanford053008
terex Sanford053008finance42
 
terex Shareholders0508
terex Shareholders0508terex Shareholders0508
terex Shareholders0508finance42
 
terex Shareholders0508
terex Shareholders0508terex Shareholders0508
terex Shareholders0508finance42
 
terex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Confterex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Conffinance42
 
terex Sanford053008
terex Sanford053008terex Sanford053008
terex Sanford053008finance42
 
terex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Confterex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Conffinance42
 
terex KeyBanc060508
terex KeyBanc060508terex KeyBanc060508
terex KeyBanc060508finance42
 
terex KeyBanc060508
terex KeyBanc060508terex KeyBanc060508
terex KeyBanc060508finance42
 
terex Wachovia062508
terex Wachovia062508terex Wachovia062508
terex Wachovia062508finance42
 
terex Wachovia062508
terex Wachovia062508terex Wachovia062508
terex Wachovia062508finance42
 

Plus de finance42 (20)

saic annual reports 2003
saic annual reports 2003saic annual reports 2003
saic annual reports 2003
 
saic annual reports 2004
saic annual reports 2004saic annual reports 2004
saic annual reports 2004
 
saic annual reports 2005
saic annual reports 2005saic annual reports 2005
saic annual reports 2005
 
saic annual reports 2006
saic annual reports 2006saic annual reports 2006
saic annual reports 2006
 
saic annual reports 2007
saic annual reports 2007saic annual reports 2007
saic annual reports 2007
 
saic annual reports 2008
saic annual reports 2008saic annual reports 2008
saic annual reports 2008
 
terex Merrill050808
terex Merrill050808terex Merrill050808
terex Merrill050808
 
terex BofA050808
terex BofA050808terex BofA050808
terex BofA050808
 
terex Merrill050808
terex Merrill050808terex Merrill050808
terex Merrill050808
 
terex BofA050808
terex BofA050808terex BofA050808
terex BofA050808
 
terex Sanford053008
terex Sanford053008terex Sanford053008
terex Sanford053008
 
terex Shareholders0508
terex Shareholders0508terex Shareholders0508
terex Shareholders0508
 
terex Shareholders0508
terex Shareholders0508terex Shareholders0508
terex Shareholders0508
 
terex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Confterex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Conf
 
terex Sanford053008
terex Sanford053008terex Sanford053008
terex Sanford053008
 
terex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Confterex 08_06_04_JP_Morgan_Conf
terex 08_06_04_JP_Morgan_Conf
 
terex KeyBanc060508
terex KeyBanc060508terex KeyBanc060508
terex KeyBanc060508
 
terex KeyBanc060508
terex KeyBanc060508terex KeyBanc060508
terex KeyBanc060508
 
terex Wachovia062508
terex Wachovia062508terex Wachovia062508
terex Wachovia062508
 
terex Wachovia062508
terex Wachovia062508terex Wachovia062508
terex Wachovia062508
 

Dernier

The AES Investment Code - the go-to counsel for the most well-informed, wise...
The AES Investment Code -  the go-to counsel for the most well-informed, wise...The AES Investment Code -  the go-to counsel for the most well-informed, wise...
The AES Investment Code - the go-to counsel for the most well-informed, wise...AES International
 
(中央兰开夏大学毕业证学位证成绩单-案例)
(中央兰开夏大学毕业证学位证成绩单-案例)(中央兰开夏大学毕业证学位证成绩单-案例)
(中央兰开夏大学毕业证学位证成绩单-案例)twfkn8xj
 
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...amilabibi1
 
Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Sonam Pathan
 
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...Amil baba
 
Unveiling Business Expansion Trends in 2024
Unveiling Business Expansion Trends in 2024Unveiling Business Expansion Trends in 2024
Unveiling Business Expansion Trends in 2024Champak Jhagmag
 
Financial analysis on Risk and Return.ppt
Financial analysis on Risk and Return.pptFinancial analysis on Risk and Return.ppt
Financial analysis on Risk and Return.ppttadegebreyesus
 
2024 Q1 Crypto Industry Report | CoinGecko
2024 Q1 Crypto Industry Report | CoinGecko2024 Q1 Crypto Industry Report | CoinGecko
2024 Q1 Crypto Industry Report | CoinGeckoCoinGecko
 
Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Commonwealth
 
The Triple Threat | Article on Global Resession | Harsh Kumar
The Triple Threat | Article on Global Resession | Harsh KumarThe Triple Threat | Article on Global Resession | Harsh Kumar
The Triple Threat | Article on Global Resession | Harsh KumarHarsh Kumar
 
Bladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex
 
PMFBY , Pradhan Mantri Fasal bima yojna
PMFBY , Pradhan Mantri  Fasal bima yojnaPMFBY , Pradhan Mantri  Fasal bima yojna
PMFBY , Pradhan Mantri Fasal bima yojnaDharmendra Kumar
 
fca-bsps-decision-letter-redacted (1).pdf
fca-bsps-decision-letter-redacted (1).pdffca-bsps-decision-letter-redacted (1).pdf
fca-bsps-decision-letter-redacted (1).pdfHenry Tapper
 
Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfKempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfHenry Tapper
 
Managing Finances in a Small Business (yes).pdf
Managing Finances  in a Small Business (yes).pdfManaging Finances  in a Small Business (yes).pdf
Managing Finances in a Small Business (yes).pdfmar yame
 
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.ppt
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.pptAnyConv.com__FSS Advance Retail & Distribution - 15.06.17.ppt
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.pptPriyankaSharma89719
 
government_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfgovernment_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfshaunmashale756
 
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdf
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdfBPPG response - Options for Defined Benefit schemes - 19Apr24.pdf
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdfHenry Tapper
 

Dernier (20)

The AES Investment Code - the go-to counsel for the most well-informed, wise...
The AES Investment Code -  the go-to counsel for the most well-informed, wise...The AES Investment Code -  the go-to counsel for the most well-informed, wise...
The AES Investment Code - the go-to counsel for the most well-informed, wise...
 
(中央兰开夏大学毕业证学位证成绩单-案例)
(中央兰开夏大学毕业证学位证成绩单-案例)(中央兰开夏大学毕业证学位证成绩单-案例)
(中央兰开夏大学毕业证学位证成绩单-案例)
 
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...
Amil Baba In Pakistan amil baba in Lahore amil baba in Islamabad amil baba in...
 
Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713Call Girls Near Me WhatsApp:+91-9833363713
Call Girls Near Me WhatsApp:+91-9833363713
 
Monthly Economic Monitoring of Ukraine No 231, April 2024
Monthly Economic Monitoring of Ukraine No 231, April 2024Monthly Economic Monitoring of Ukraine No 231, April 2024
Monthly Economic Monitoring of Ukraine No 231, April 2024
 
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...
NO1 WorldWide Love marriage specialist baba ji Amil Baba Kala ilam powerful v...
 
Unveiling Business Expansion Trends in 2024
Unveiling Business Expansion Trends in 2024Unveiling Business Expansion Trends in 2024
Unveiling Business Expansion Trends in 2024
 
Financial analysis on Risk and Return.ppt
Financial analysis on Risk and Return.pptFinancial analysis on Risk and Return.ppt
Financial analysis on Risk and Return.ppt
 
2024 Q1 Crypto Industry Report | CoinGecko
2024 Q1 Crypto Industry Report | CoinGecko2024 Q1 Crypto Industry Report | CoinGecko
2024 Q1 Crypto Industry Report | CoinGecko
 
Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]Economic Risk Factor Update: April 2024 [SlideShare]
Economic Risk Factor Update: April 2024 [SlideShare]
 
The Triple Threat | Article on Global Resession | Harsh Kumar
The Triple Threat | Article on Global Resession | Harsh KumarThe Triple Threat | Article on Global Resession | Harsh Kumar
The Triple Threat | Article on Global Resession | Harsh Kumar
 
Bladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results PresentationBladex 1Q24 Earning Results Presentation
Bladex 1Q24 Earning Results Presentation
 
PMFBY , Pradhan Mantri Fasal bima yojna
PMFBY , Pradhan Mantri  Fasal bima yojnaPMFBY , Pradhan Mantri  Fasal bima yojna
PMFBY , Pradhan Mantri Fasal bima yojna
 
fca-bsps-decision-letter-redacted (1).pdf
fca-bsps-decision-letter-redacted (1).pdffca-bsps-decision-letter-redacted (1).pdf
fca-bsps-decision-letter-redacted (1).pdf
 
Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfKempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
 
Managing Finances in a Small Business (yes).pdf
Managing Finances  in a Small Business (yes).pdfManaging Finances  in a Small Business (yes).pdf
Managing Finances in a Small Business (yes).pdf
 
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.ppt
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.pptAnyConv.com__FSS Advance Retail & Distribution - 15.06.17.ppt
AnyConv.com__FSS Advance Retail & Distribution - 15.06.17.ppt
 
government_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdfgovernment_intervention_in_business_ownership[1].pdf
government_intervention_in_business_ownership[1].pdf
 
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdf
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdfBPPG response - Options for Defined Benefit schemes - 19Apr24.pdf
BPPG response - Options for Defined Benefit schemes - 19Apr24.pdf
 
Q1 2024 Newsletter | Financial Synergies Wealth Advisors
Q1 2024 Newsletter | Financial Synergies Wealth AdvisorsQ1 2024 Newsletter | Financial Synergies Wealth Advisors
Q1 2024 Newsletter | Financial Synergies Wealth Advisors
 

tenet healthcare EarningsPreparedRemarks

  • 1. Tenet’s Q4 2007 Earnings Call Prepared Remarks February 26, 2008 Trevor Fetter, President and Chief Executive Officer Good morning everyone. This quarter we achieved a major milestone by generating positive growth in admissions. We also continued to demonstrate positive trends in several key areas and certain leading indicators have never looked stronger. I feel that the health and trajectory of this company is better than at any time in the recent past. This was the first time in nearly four years that we had positive admissions in a quarter. Because it was just slightly positive, I want to add some color to the statistic. First, we’ve had more consistent results among our regions than in past quarters, and we’ve continued to move more hospitals into positive admissions territory. Admissions in Florida stabilized significantly to just below breakeven, compared to the declines of more than 3 percent that we had been reporting in recent quarters. More importantly, the improving trend has accelerated into the first quarter of 2008, with same-hospital admissions up 2.3 percent through January. Florida admissions growth was positive for the first time since Q104, with an increase of more than 2 percent for the month. This upward trend has continued into February in both Florida and across the company. Even the trend in outpatient visits has improved. Same-hospital commercial managed care revenues increased by almost 9 percent despite a nearly 2 percent decline in commercial admissions. This is the single largest quarterly revenue increase we’ve reported in five years. We are positioned for further pricing strength as a result of the numerous managed care contracts we announced recently. In fact, these
  • 2. contracts, with United, Cigna and Blue Cross of California represent a third of our total commercial managed care portfolio. And once again we kept the growth in controllable expenses on a unit of service basis at or below that reported by our peers. The innovations we’ve made in the revenue cycle continue to produce tangible results, despite the challenge represented by the continued double-digit increases in uninsured admissions. Because of these efforts, we were able to increase our collection rates from both insured and uninsured individuals. We also improved sharply in the non-financial metrics which we believe are important to our longer-term performance. These metrics are part of our Balanced Scorecard and incentive plan, and we believe they are leading indicators of our continued progress. We break the Balanced Scorecard into five areas, or pillars, which include quality, service, people, cost and growth. The first of our three non-financial metrics falls into our quality pillar. According to CMS’ most recently published Hospital Compare data, Tenet scores higher than any other investor- owned hospital company in CMS’ core measures, and we have the third highest score among the top 10 largest hospital systems in the country. We continue to hit all-time highs in our quality statistics even as CMS adds challenging new metrics to the mix. The next pillar is service. Our scores here improved as well, with physician satisfaction increasing 2 ½ percent over the prior year and patient satisfaction increasing nearly 1 percent. And in the people pillar, total employee turnover improved by more than 12 percent. Employee satisfaction improved nearly 4 percent. And although it’s not a balanced scorecard metric, I know you would find it interesting that our hospital CEO turnover in 2007 was just under 4 percent. This compares to a 20 percent turnover among our hospital CEOs in 2006. Q4 2007 Earnings Prepared Remarks Page 2 of 19
  • 3. While we didn’t generate as much cash from working capital as we had planned, we did offset that at year-end with our other cash initiatives, which we expect will continue generating value going forward. Biggs will comment on those in a moment. Near the end of 2007, we engaged in a thorough business planning effort that resulted in the outlook we stated in this morning’s press release. This outlook envisions 2008 EBITDA in a range of $775 million to $850 million, and 2009 EBITDA of $1 billion or better. While I fully recognize the billion dollar objective represents a significant improvement from the EBITDA we generated in 2007, I believe we’ve set a clear path to achieving it. This will require strong and consistent performance on our part – capturing market share from competitors to meet our volume objectives, continuing to implement innovative techniques to offset the challenges on bad debt, and extending the progress that we’ve made in controlling costs and achieving enhanced pricing – but it is certainly within our reach. With that as an overview, let me turn the call over to our chief operating officer, Dr. Steve Newman, who will provide you with some commentary on what is driving our improvement in patient volumes. Steve… Stephen Newman, M.D., Chief Operating Officer SLIDE 6: Stephen L. Newman, M.D. – Chief Operating Officer Thanks, Trevor. And good morning, everyone. We made very gratifying progress in the fourth quarter that is continuing in the first quarter. In my opinion, our turnaround is accelerating and is increasingly evident in a number of areas. SLIDE 7: Momentum Building in 3 Key Areas To show you why I believe this, I’ll give you a flavor for our momentum in three key areas: volumes, pricing and its relationship to our quality initiatives, and our progress in expanding our medical staffs. I’ll also touch on the improvements we’re driving in Florida and the successes we’ve achieved in our new managed care contracts. Q4 2007 Earnings Prepared Remarks Page 3 of 19
  • 4. SLIDE 8: Volume Growth Let’s start with volumes. Fourth-quarter same-hospital aggregate admissions increased a tenth of a percentage point over Q406. That’s the first positive quarter for admissions growth in almost four years. January’s in-patient admission growth was 2.3 percent and February has continued that trend, so I think it’s clear that our volumes are on an upward trajectory. The progress in the fourth quarter and in January is especially gratifying when you remember that we had a mild flu season until four weeks ago. It’s not our normal practice to disaggregate volume results – and we make no promise to do this on a regular basis – but I think some drill down this time will help you understand the underlying trends we’re seeing. In our key Florida market, fourth-quarter in-patient admissions were down just three tenths of a point – our best performance there since Q404. In Palm Beach County fourth-quarter admissions actually increased 80 basis points. Four of our five Palm Beach hospitals had positive year-over-year admissions growth. Additional evidence of our Florida recovery is demonstrated by January admissions being up more than 2 percent over January 2007. Our new Florida regional leader, Marsha Powers, has accelerated our physician recruitment, redirection and employment activities. We’re confident we’re finally on the road to sustainable growth in that important market. Now I can’t resist saying a few words about the remarkable and continuing progress of our Philadelphia market. Both Hahnemann University Hospital and St. Christopher’s Hospital for Children generated strong volume gains in the fourth quarter. As you know, we expected to gain volume at St. Chris because of the closure of Temple University Hospital for Children. But the gains at St. Chris have far exceeded what can be attributed just to that new affiliation. For the quarter, admissions at St. Chris were up 20 percent, which translates to an additional 498 admissions compared with the same quarter the year before. Also contributing to that success at St. Chris are our aggressive outreach activities beyond the five-county metro Philadelphia area as well as the addition of new high-end services like bone marrow transplantation. Q4 2007 Earnings Prepared Remarks Page 4 of 19
  • 5. Meantime, Hahnemann’s admissions were up nearly one percent. We are continuing to work with Drexel University’s School of Medicine to grow our faculty practices at Hahnemann and St. Chris to benefit the educational, research and patient care missions of both organizations. We’re in the process of expanding our facilities in Philadelphia in anticipation of future growth, but we have sufficient capacity there today to handle the projected increases in volume over the near term. California was another bright spot in the quarter. Our California hospitals had an aggregate increase in admissions of 3.2 percent over the fourth quarter of 2006. We knew we’d see an improvement in the quarter because of our acquisition of the Stanislaus Behavioral Health Center in Modesto, but we also had noticeable increases in two of our other key California markets – the Palm Springs area and Orange County. For example, Fountain Valley was up 3.8 percent and Desert Regional increased admissions by 9 percent for the quarter. The Stanislaus facility added 263 admissions to the California aggregate total. But, even without that added volume, California admissions were up a solid 2.4 percent. We encountered some volume weakness in our Texas and Southern States markets, but we believe that softening will be temporary. One weak spot in the quarter was El Paso, but we have already seen improved admission volumes in early 2008. A major refurbishing project at another one of our Texas hospitals temporarily closed a number of our medical-surgical units there. In our Houston market, we’re about to pass the first anniversary of an aggressive new physician-owned competitor that hurt another of our hospitals. We expect that situation to normalize in the near future. The challenges in our Southern States region were very local in the fourth quarter. These resulted from slightly higher than expected physician attrition. We have taken swift action to accelerate our volume-building activities in both the Southern States and Texas markets. SLIDE 9: Volume Growth (Cont.) Q4 2007 Earnings Prepared Remarks Page 5 of 19
  • 6. I’ll wrap up this discussion of volumes with brief comments on surgery volumes and commercial managed care admissions. Our total surgeries rose three-tenths of a point compared to Q406. Out-patient surgeries were up eight-tenths of a point while in-patient surgeries were down four-tenths of a point. This represents a dramatic improvement over the losses we had absorbed in total surgeries during prior quarters. As recently as the first half of 2007, quarterly declines in surgeries were 5 percent or more. Same-hospital commercial managed care admissions were down 1.8 percent in the fourth quarter. Our commercial managed care volume weakness was concentrated in Texas and the Southern States. Specifically, three hospitals located within our Texas market and Southern States region were responsible for 96 percent of this decrease company wide. As I just described a few moments ago, we expect that situation to stabilize in the near future. We continued to generate growth in many of the TGI service lines I highlighted in the third quarter. Commercial urologic surgery admissions were up 8.2 percent, ENT surgery was up 19 percent, orthopedic surgery was up 0.3 percent, neurosurgery was up 3.7 percent, and vascular surgery was up 16 percent for the fourth quarter. Meantime, obstetrics was down 2.7 percent, and open heart surgery was down nearly 14 percent or 68 procedures. Overall, I’d say the key takeaway about our latest admissions performance is that we are continuing to drive growth in the service lines we targeted as part of our Targeted Growth Initiative (TGI). As you recall, over the past three years through TGI we painstakingly identified the service lines with the best growth and profit potential at each of our hospitals. SLIDE 10: Pricing Gains . . . achieving our objectives Now let’s talk about pricing. We successfully renegotiated several of our major managed care contracts in the fourth quarter and the first six weeks of 2008. With the completion of new, multi-year contracts with United, Aetna, CIGNA and Blue Cross of California, we now have secured full network participation with every one of our major commercial payers for all of our hospitals, freestanding ambulatory surgery centers, diagnostic imaging centers and Q4 2007 Earnings Prepared Remarks Page 6 of 19
  • 7. physician practices. These new contracts will also automatically add any new facilities or practices we might acquire during the term of the agreements. As you know, making sure that all our facilities are network providers has been a top priority of our managed care strategy, and I am pleased to tell you that we have now achieved that goal with our recently completed contracts. Our managed care pricing – including managed government programs – was up sharply with net inpatient revenue per admission increasing 9.4 percent and net outpatient revenue per visit up 9.0 percent in the fourth quarter. I believe that is a reflection of a number of focused efforts to align our Targeted Growth Initiative with our managed care strategy. Another of our managed care goals has been to qualify for as many managed care Centers of Excellence programs as possible. Additionally, in the last four months we have executed two contracts that actually provide potential incremental reimbursement to our hospitals for meeting mutually agreed upon clinical quality goals. SLIDE 11: Physician Relationships: Recruiting More Doctors Before I conclude, I want to share with you the latest results of our efforts to expand medical staffs at all our hospitals. In the fourth quarter, net of normal attrition, we added 241 new active staff physicians to our hospitals. For all of 2007, we added a net total of 1,086 physicians. As you know, this has been a critical priority for us. The success of our efforts in this area is especially gratifying for me, and it bodes well for the future growth of our hospitals. I truly believe that this progress in physician recruitment is a key indicator of our future volume growth. In the last year, we have increased the number of physicians with privileges to admit patients to our hospitals by almost 9 percent. It will take time for these new relationships to fully mature, but this growth represents a dramatic reversal of the erosion in our affiliated physician base that we experienced over the past several years. If I had to point to the one item that gives me the most optimism about our future at Tenet, this would be it. Q4 2007 Earnings Prepared Remarks Page 7 of 19
  • 8. Through our Physician Relationship Program, we visited 4,720 physicians during the fourth quarter. Of those we visited, we saw an increase in admissions of 2.5 percent from physicians who already had staff privileges at our hospitals. We also visited 437 physicians who did not have privileges at our hospitals, and we expect many of them to apply for privileges as a result of our visits. This is an integral part of our strategy to gain market share in many of our fiercely competitive markets. To assist in these and all our volume-building efforts, during the fourth quarter we hired Lloyd Mencinger to lead our business development, marketing, advertising, physician recruitment and the Physicians Relationship program. Lloyd has years of experience in business development, working at both Baxter and Boston Scientific. SLIDE 12: Summary - Operations So, to conclude, the bottom line from my perspective is this: In the fourth quarter, we made progress in all the major drivers of performance in our business. We grew in-patient volumes for the first time in almost four years. We’ve continued to do that in 2008. From a pricing, quality and physician recruitment perspective, we continue to grow our channels for new business. Overall, I am very pleased by the trends I am seeing, and I am confident that we will continue to see improvements in 2008. With that, I will turn things over to Biggs Porter, our chief financial officer. Biggs? Biggs Porter, Chief Financial Officer Thank you, Steve, and good morning everyone. In the interest of time, I’m not going to repeat a lot of the numbers in our earnings release or 10-K. I’ll limit my comments to providing a relevant context for our disclosures. Q4 2007 Earnings Prepared Remarks Page 8 of 19
  • 9. In the fourth quarter, we benefited from pricing, cost control, bad debt mitigation and stabilized volume. We finished the year with adjusted EBITDA in the middle of our last outlook and just within the outlook range we started out with last March. There were two unusual items in the quarter which largely offset each other. The first was a net charge of $12 million related to year-end accruals for compensation and benefits. This included adjustments to a predecessor company’s pension plan, union settlement costs in Florida, workers compensation adjustments and year-end incentive plan accruals. The other item is a favorable adjustment to our bad debt reserve of $19 million. This reserve is set through the use of an 18-month “look-back” on our collection history. As you know, our collection rates continue to show modest improvement across most customer segments. In recent quarters our results have often included cost report settlements, generally with favorable impact. The impact this quarter was effectively a net zero. With that brief analysis in mind, let me offer a few thoughts on the drivers that got us to those results. Steve has already covered volumes, so without detail, I will just reiterate how pleased we are to see aggregate positive growth, particularly considering the well advertised strong headwinds in the industry. I also want to note that our uninsured and charity volumes actually declined in January – so the positive 2.3 percent in admission growth Trevor referred to earlier will contribute to our bottom line. Now on to revenues, Fourth quarter same hospital revenues rose to $2.2 billion, an increase of 6 percent. Because of the essentially breakeven volume growth, this 6 percent revenue increase was principally due to pricing. Q4 2007 Earnings Prepared Remarks Page 9 of 19
  • 10. Slide 18 on the web shows that we experienced solid progress in all our key pricing metrics. As a summary metric, normalized for cost report adjustments in 2006, net patient revenues per adjusted admission were up 4.9 percent. As a number of important contracts including Blue Cross of California and CIGNA were not effective until the first quarter of 2008, we anticipate additional pricing increases to contribute to our 2008 earnings. Substantially all of our existing contracts, including those negotiated in 2007, also have 2008 and 2009 escalators built in. We have good visibility into our managed care pricing for the next two years, because approximately 80 percent of our commercial rates for 2008 and over 60 percent for 2009 are already covered in signed contracts. Turning to costs, Same hospital controllable operating expense per adjusted patient day increased by 5.1 percent. As I mentioned a moment ago, this included a $12 million expense accrual for compensation and benefits expense. If we normalize for that accrual and the higher supplies expense on greater implant utilization, our expenses would have been in line with the expectations we had going into the quarter, with a number of lesser puts and takes among the other elements of our controllable costs. It is also important to note that we had a $13 million reduction in malpractice expense in the quarter. Based on the investment we have made in clinical quality, we are pleased to see this reduction. Unfortunately, we also had some poorer than expected cost performance in a few of our hospitals that lost volume in the quarter. We believe, as Steve mentioned, that both the volume and cost effects of that will reverse themselves. On Bad Debt, Q4 2007 Earnings Prepared Remarks Page 10 of 19
  • 11. Same hospital uninsured admissions rose by 10 percent in the fourth quarter and revenues from the uninsured rose by 17.5 percent. Let me remind you, that this increase in uninsured revenue has been influenced by our recent efforts to improve the accuracy of acuity capture in our emergency departments. Any change in uninsured billings creates a parallel effect on bad debt expense. We estimate that $19 million of the $24 million in the uninsured revenue increase year over year is attributable to our efforts to improve the accuracy of acuity capture in our emergency departments and, to a much lesser degree, charge master increases. The corresponding $17 million bad debt increase has no effect on the bottom line since it is offset by revenue increases. Also, since we modified our ED charge capture process in the second quarter of 2007, we do not expect similar year-over-year increases in bad debt from ED charge capture in 2008. Growth in bad debt expense from higher uninsured admissions was approximately $5 million. Accordingly, the combined effect on bad debt of uninsured admission growth and pricing compared to last year is approximately $22 million dollars. Offsetting the adverse impact on bad debt expense from the growth in the uninsured has been continued progress on improving collections. Through focused effort, we have been successful in raising self-pay collection rates to 36 percent in the fourth quarter from 32 percent a year ago. Managed care collection rates also moved up to 98 percent in the fourth quarter, from 97 percent a year ago due to lower denials attributable to our previously discussed efforts to improve this area. These include greater Interqual screening, clearer contracting arrangements and better front-end processes. This improvement in collection experience led to the recording of the $19 million favorable adjustment to our bad debt reserves I mentioned at the beginning of my remarks. This compared to an $8 million favorable adjustment last year. Q4 2007 Earnings Prepared Remarks Page 11 of 19
  • 12. In addition to the overall collection performance improvements, we also resolved older managed care accounts which had been heavily reserved. The favorable effect of this on bad debt expense was offset by what we see primarily as the seasonal aging of self-pay accounts. Like others in the industry, we typically experience a slowing of payments in the fourth quarter as our patients deal with year-end and holiday pressures on their household budgets. This is typically reversed by the end of the first quarter. So to summarize, same hospital bad debt expense grew over the prior year fourth quarter by $15 million. Uninsured volumes contributed $5 million to this increase, pricing contributed $17 million, and the net year-over-year reserve adjustment due to improved collections experience was a favorable offset of $10 million. Other variances, including the effects of the settlement of managed care disputes, netted to $3 million. While same hospital uninsured admissions and revenues were up over prior year fourth quarter, charity was down, making this another quarter in which there are opposing trends. Although not easily traced, we are optimistic that our strategies to emphasize favorable product lines and manage elective admissions and visits by uninsured are mitigations to what is a key risk in the industry. I emphasize the word “elective” in this regard. We also continue to drive on best practices in our billing and collection activities. I just did a fourth quarter year-over-year comparison on bad debts, but if you compare sequentially, it is important to note that uninsured revenues were actually down from the third quarter of this year. Turning to cash flow and capital expenditures, We ended the year with our cash balance within our expected range. In accomplishing that we didn’t do as well on cash from operations as we expected and spent slightly more capital, which should just be a matter of timing, but we continued to find other positive sources of cash on our balance sheet, which are more permanent in nature. As I will discuss in a moment, the variances to our expectations in the fourth quarter will turn to expectations of improved free cash flow and cash generated from operations in 2008. Q4 2007 Earnings Prepared Remarks Page 12 of 19
  • 13. Cash from operations and free cash flow become sequentially more important metrics as we proceed through the next few years and approach the refinancing of our debt. In this respect you should consider 2007 as the year of heaviest investment for the company, with volumes starting to show the benefits, and with us well positioned to show improved earnings, cash flow and return on investment going forward. Capital expenditures in continuing operations were $300 million in the quarter. This figure was slightly above the higher end of our range we shared with you in our third quarter call and is roughly equivalent to the amount we spent last year. One of the influences on the higher spending in this year’s fourth quarter was that we wanted to make sure 2007 was our “catch up” year as we have previously projected. This leaves us with a manageable amount of carryover projects. On the Web we have included on Slide 23 a listing of the major capital projects of 2007. At this point I expect capital spending in 2008 to be little more front end loaded into the first and second quarters Also contributing to the higher level of capex in the fourth quarter, favorable weather has allowed us to accelerate the construction of our Sierra Providence East Medical Center in El Paso, which will now open a month earlier than we had expected. This generated $22 million in capex in the fourth quarter. We have also started the construction of a replacement hospital for our East Cooper facility outside of Charleston, South Carolina on which we spent $2 million in the fourth quarter. With respect to cash flow, Adjusted cash flow provided from continuing operations came in at $127 million for the fourth quarter and was lower than anticipated. The primary deviation was in working capital. We typically expect to see a more significant build-up in accounts payable and accrued liabilities at year-end than we saw this year. On the pure accounts payable side, we saw the increase we anticipated in the payment terms set up in the system. However, there was a $63 Q4 2007 Earnings Prepared Remarks Page 13 of 19
  • 14. million decline in book overdrafts at December 2007 compared to 2006 which occurred due to the timing of our year-end check processing. This book overdraft should return to more normal levels in 2008, thus creating a source of cash flow in 2008. We also experienced a $31 million build up in Accounts Receivable. This is attributable to the effects of higher revenues and lower reserving for bad debts. This therefore doesn’t reflect bad performance. It in fact reflects improved collectability. However, we did not generate the net improvement we targeted in accounts receivable. In the fourth quarter of this year we did resolve a number of our older managed care receivables, but this was offset by the seasonal aging of self-pay accounts I referred to earlier. Other than that, we were overly optimistic in our ability to reduce accounts receivable over the course of one quarter. We believe it is going to take a few more quarters into 2008 to accomplish this reduction. Just to summarize the influences on 2007 in total, we had a net reduction in our book overdraft of $63 million, a reduction in accounts receivable credit balances of $54 million, and non-cash income related to prior year cost report adjustments of approximately $35 million. Not all of these affect cash from continuing operations dollar for dollar, but they did have a significant impact. We do not expect similar aggregate impact from these items in 2008. Accordingly, in 2008, as we indicated in the release, we anticipate having adjusted cash provided from operating activities of $400 to $500 million. This compares to $209 million in 2007 for an improvement in the range of $190 million to $290 million. Higher EBITDA is expected to contribute $75 to $150 million of this improvement. The remainder of the improvement includes a restoration of a more normal book overdraft position at year-end 2008, the two day reduction in accounts receivable we previously stated as an objective for the fourth quarter of 2007, and a reduction in the rate of pay down of credit balances. As I have said previously, we have engaged in a review to increase the efficiency of our balance sheet and correspondingly free up cash and increase return on invested capital. Let me now turn to the progress we achieved towards this end in the fourth quarter. We added $129 million in cash from these initiatives in 2007, of which $97 million was in the fourth Q4 2007 Earnings Prepared Remarks Page 14 of 19
  • 15. quarter. At the corporate level, we monetized certain investments previously residing in our insurance subsidiaries and liquidated the cash surrender value of life insurance policies. We anticipate that continuing efforts to execute on this initiative can generate incremental cash ranging from $400 million to $600 million over the next 24 months. These include the sale of our medical office buildings, the recapitalization of Broadlane, in which we hold a 48% interest, and the sale or monetization of other excess land, buildings and other underutilized and inefficient assets. Since some of these items require marketing and price negotiation, I am not going to break them down into separate component values. Because the timing and value is within a broad range, at this time this additional cash is not in our 2008 year-end outlook. Before I turn to the outlook for 2008, I want to comment on the impairments we recorded in the quarter. They were much reduced over the prior year and included no impairments of goodwill. This is a sign that our turnaround is progressing and that our forecasts at the hospital level are for a broad based recovery. The single biggest reason for the impairments we recorded was the prospective reduction of Medicaid funding in Georgia and not attributable to our execution of our turn around strategies With respect to capital spending, For 2008 we expect Capital expenditures to be in the range of $600 to $650 million. This includes $82 million for new hospital construction, $32 million for seismic and American Disabilities Act requirements, and $25 million for Outpatient growth. Investors have often asked us to identify the portion of our capital expenditures which can be thought of as “maintenance” capex. Because of the many judgment calls necessary to distinguish maintenance capex from capital expenditures intended to grow the business, we have been reluctant to specify a number. By example, if we replace an old 4-slice CT scanner with a 64-slice scanner is that replacement or expansion? Intuitively, I would call that maintenance capital, although it may expand our capabilities. Our answer to date to the question of maintenance capital has been to point investors to the sum of depreciation, amortization and lease expense, net of implicit interest, which was approximately $500 Q4 2007 Earnings Prepared Remarks Page 15 of 19
  • 16. million in 2007. Another way to look at this might be how much did we spend on our current core hospitals over the period 2003 to 2005 excluding physical expansion and new hospital construction. This was approximately $400 million per year over that period. If you look at the same statistic for the last five years, it was approximately $450 million. If you put all this together, then it would suggest an estimate of “maintenance capital” at approximately $400 to $500 million. Having said that, the lower end of the range, or $400 million, would likely not sustain our competitive position over a long term. Also, this excludes seismic and American Disability Act requirements as well as capital for expansion of the enterprise or in certain cases the construction or technology spending necessary to protect market share based on the action of our competitors. If you include those, it takes us up to the $600 to $650 million level we have spoken to as a reasonable level of average annual spend to meet regulatory requirements, and sustain and grow the enterprise. Moving to the Outlook, We have provided extensive detail with regard to our 2008 Outlook in this morning’s press release, so I won’t repeat all the line item detail here. The 2008 Outlook includes an expectation of adjusted EBITDA in the range of $775 to $850 million – or growth of 10 to 20 percent over the $701 million of adjusted EBITDA for 2007. Much of the “heavy lifting” necessary to achieve performance at this level has already been accomplished. I’m referring here to the contracts we recently signed with our major managed care payers, and the other pricing initiatives and cost efficiencies we implemented last year that will achieve full run rate in 2008. Having said that, there clearly also were some set backs, most notably the $60 million revenue loss from the Medicaid reductions in Georgia and Florida. We haven’t given a 2008 outlook previously, and over the course of last year, we maintained a 2009 outlook which, while having a lot of subjectivity, was between $1 and $1.1 billion of adjusted EBITDA. In the fourth quarter we updated the analysis indicating that of the $100 Q4 2007 Earnings Prepared Remarks Page 16 of 19
  • 17. million of risk inherent in that range, $60 million had now been consumed by the Medicaid reductions I just referred to in Georgia and Florida. This still left us with a 2009 outlook of $1 billion or higher going into the detailed 2008 planning process. We have completed that process and continue to believe that the $1 billion or more of EBITDA in 2009 is achievable, although projecting two years out is by its nature very subjective. As I said, we have given a range of $775 to $850 million for EBITDA in 2008. Clearly, if we do not perform in the upper half of that range in 2008, reaching $1 billion or more in 2009 becomes a very significant challenge. As I said though, we continue to believe the objective is achievable, based on our progress in pricing, cost control and positive progress toward our volume objectives. If you ask me where the greatest areas of risk are that lead to the 2008 range or would cause us not to make the 2009 target, I would say the following two things stand out: • First: Although it seems we are turning the corner on volumes, this is, of course, a very subjective estimate. Equally important, mix between patients and payer categories can have a significant influence. To obtain $850 million in 2008 or $1 billion in 2009, we either need to have relatively stable mix overall and a limited increase in the percentage of uninsured and charity volumes combined, or we need to get offsetting yield from our bad debt initiatives. • Second: We need to have broad-based volume growth. If we achieve our aggregate volume objectives, but volumes remain volatile at the hospital level, it will remain difficult to capture the operating leverage of fixed cost absorption. Although we have seen a reduction in the variability of performance at the hospital level overall, if we have a significant number of hospitals that suffer volume decline in 2008, that will make the achievement of an aggregate 40 percent yield on volume growth more challenging. In slide 26 on the web, we have included a sample walk forward from 2007 actual results to 2008 at $850 million and 2009 at $1 billion of EBITDA. This is a sample walk forward, illustrating one path to our objective of $1 billion, or more, of adjusted EBITDA in 2009. It is not intended to give a series of spot estimates or line item guidance. There are certainly other Q4 2007 Earnings Prepared Remarks Page 17 of 19
  • 18. combinations of line item performance which would produce the same, or higher or lower results. Having said that, this walk forward shows how the cost and price actions drive value relative to the more subjective estimates of volume and mix. In a nut shell, volumes drive approximately 33 percent of the necessary improvement in the walk forward from an adjusted 2007 starting point, with our cost and price actions providing the rest. You may recall that initiatives in place by the end of 2007 were estimated to achieve $118 million of improvement in 2008 and 2009 compared to that achieved in 2007. In the walk forward, the combined EBITDA effect of the initiatives now amount to $162 million, with $33 million related to revenue and $129 million related to cost. We have not assigned any value into the walk forward for our bad debt initiatives. We have thus implicitly assumed that the financial contribution of our bad debt initiatives will act to mitigate any potential increase in the uninsured or under-insured. The walk forward shows the effect of our cost and price actions and their effect on 2008 relative to 2007 in order to bridge to our prior disclosures of these initiatives. Since these are now imbedded in our recent actual results and in our budgets, subject primarily to just full run rate benefits, I will probably not keep isolating them going forward as they have become integral to our operations and are no longer discrete. This does not mean that we are not tracking execution of those plans and budgets. We are. In terms of the incremental lift from rate parity adjustments in managed care pricing we reflected in the walk forward, I can report that we are now negotiated on 100 percent of this in 2008 and 80 percent in 2009. There is still some potential additional pricing upside beyond those numbers. So, as I said before, we feel very confident about our pricing estimates, subject to any unforeseen regulatory change or mix changes. You will note that the walk forward starts by backing two amounts out from the $701 million 2007 adjusted EBITDA starting point: 1) the effect of the 2008 Georgia and Florida Medicaid reductions, and, conservatively, 2) $40 million of the 2007 prior year cost report income Q4 2007 Earnings Prepared Remarks Page 18 of 19
  • 19. We may, in fact, have some effect of cost report adjustments in 2008 or 2009, but for now, we have taken $40 million of cost report adjustments out of the walk forward. By eliminating these two items at the start, our 2007 starting point for the walk-forward is a conservative $601 million. This conservative starting point of $601 million does make us more reliant upon volumes than in our prior walk forward. It now takes growth in volume-related revenues over the two year period in this sample walk forward, of approximately 2.2 percent in 2008 and 1.7 percent in 2009. Please remember that approximately 1 percent of this volume growth in 2008 is expected from the recent additions of Stanislaus and the closing of Temple Children’s hospital. Last year after we gave our 2006 results and 2007 outlook, some analysts tried to annualize our fourth quarter as a means of estimating what the next year should look like. I caution against this as it does not consider the effect of projected volume growth and the full run rate benefit of our 2007 initiatives. It also would not reflect that we have negotiated price increases on contracts beginning as early as January 1 of this year and that our annual wage increases are phased in later and are primarily in October, creating timing advantage between price and cost escalation. I know that was a lot to digest, so before we go to Q&A, I’d like to summarize briefly, • we showed real progress on volumes and pricing and took significant cost actions in the quarter, • we believe this progress is sustainable and that we can continue to leverage those actions to produce much improved results in 2008 and 2009, • and, we are driving on cash and return on invested capital as a key indicator of shareholder value growth. Let me now ask our operator to assemble the queue for questions. Q4 2007 Earnings Prepared Remarks Page 19 of 19